p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
integrates_VBZ
phosphatidylinositol_NN
3-kinase_NN
and_CC
rapamycin-regulated_JJ
signals_NNS
for_IN
E2F_NN
regulation_NN
in_IN
T_NN
lymphocytes_NNS
._.

In_IN
T_NN
lymphocytes_NNS
,_,
the_DT
hematopoietic_JJ
cytokine_NN
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
uses_VBZ
phosphatidylinositol_NN
3-kinase_NN
-LRB-_-LRB-
PI_NN
3-kinase_NN
-RRB-_-RRB-
-_:
induced_JJ
signaling_NN
pathways_NNS
to_TO
regulate_VB
E2F_NN
transcriptional_JJ
activity_NN
,_,
a_DT
critical_JJ
cell_NN
cycle_NN
checkpoint_NN
._.

PI_NN
3-kinase_NN
also_RB
regulates_VBZ
the_DT
activity_NN
of_IN
p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
,_,
the_DT
40S_JJ
ribosomal_JJ
protein_NN
S6_NN
kinase_NN
,_,
a_DT
response_NN
that_WDT
is_VBZ
abrogated_VBN
by_IN
the_DT
macrolide_NN
rapamycin_NN
._.

This_DT
immunosuppressive_JJ
drug_NN
is_VBZ
known_VBN
to_TO
prevent_VB
T-cell_NN
proliferation_NN
,_,
but_CC
the_DT
precise_JJ
point_NN
at_IN
which_WDT
rapamycin_NN
regulates_VBZ
T-cell_NN
cycle_NN
progression_NN
has_VBZ
yet_RB
to_TO
be_VB
elucidated_VBN
._.

Moreover_RB
,_,
the_DT
effects_NNS
of_IN
rapamycin_NN
on_IN
,_,
and_CC
the_DT
role_NN
of_IN
p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
in_IN
,_,
IL-2_NN
and_CC
PI_NN
3-kinase_NN
activation_NN
of_IN
E2Fs_NNS
have_VBP
not_RB
been_VBN
characterized_VBN
._.

Our_PRP$
present_JJ
results_NNS
show_VBP
that_IN
IL-2_NN
-_:
and_CC
PI_NN
3-kinase-induced_JJ
pathways_NNS
for_IN
the_DT
regulation_NN
of_IN
E2F_NN
transcriptional_JJ
activity_NN
include_VBP
both_CC
rapamycin-resistant_JJ
and_CC
rapamycin-sensitive_JJ
components_NNS
._.

Expression_NN
of_IN
a_DT
rapamycin-resistant_JJ
mutant_NN
of_IN
p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
in_IN
T_NN
cells_NNS
could_MD
restore_VB
rapamycin-suppressed_JJ
E2F_NN
responses_NNS
._.

Thus_RB
,_,
the_DT
rapamycin-controlled_JJ
processes_NNS
involved_VBN
in_IN
E2F_NN
regulation_NN
appear_VBP
to_TO
be_VB
mediated_VBN
by_IN
p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
._.

However_RB
,_,
the_DT
rapamycin-resistant_JJ
p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
could_MD
not_RB
rescue_VB
rapamycin_NN
inhibition_NN
of_IN
T-cell_NN
cycle_NN
entry_NN
,_,
consistent_JJ
with_IN
the_DT
involvement_NN
of_IN
additional_JJ
,_,
rapamycin-sensitive_JJ
pathways_NNS
in_IN
the_DT
control_NN
of_IN
T-cell_NN
cycle_NN
progression_NN
._.

The_DT
present_JJ
results_NNS
thus_RB
show_VBP
that_IN
p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
is_VBZ
able_JJ
to_TO
regulate_VB
E2F_NN
transcriptional_JJ
activity_NN
and_CC
provide_VB
direct_JJ
evidence_NN
for_IN
the_DT
first_JJ
time_NN
for_IN
a_DT
link_NN
between_IN
IL-2_NN
receptors_NNS
,_,
PI_NN
3-kinase_NN
,_,
and_CC
p70_NN
-LRB-_-LRB-
s6k_NN
-RRB-_-RRB-
that_WDT
regulates_VBZ
a_DT
crucial_JJ
G1_NN
checkpoint_NN
in_IN
T_NN
lymphocytes_NNS
._.

